Recombinant Vaccines

Global Recombinant Vaccines Market to Reach US$19.1 Billion by 2030

The global market for Recombinant Vaccines estimated at US$10.9 Billion in the year 2024, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2024-2030. Subunit Recombinant Vaccines, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$10.6 Billion by the end of the analysis period. Growth in the Attenuated Recombinant Vaccines segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 13.2% CAGR

The Recombinant Vaccines market in the U.S. is estimated at US$3.0 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$3.8 Billion by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.2% and 8.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Recombinant Vaccines Market - Key Trends & Drivers Summarized

How Are Recombinant Technologies Redefining Vaccine Development and Delivery?

Recombinant vaccine platforms have revolutionized the global immunization landscape by enabling the production of highly specific, stable, and safe vaccine antigens using genetic engineering. Unlike traditional inactivated or live-attenuated vaccines, recombinant vaccines rely on the expression of select antigens in host cells such as yeast, bacteria, or mammalian systems, minimizing the risk of pathogen reactivation or contamination. This technology is increasingly adopted for diseases where traditional vaccines have failed to deliver long-term efficacy or safety, including HPV, hepatitis B, and shingles. Moreover, the flexibility of recombinant platforms allows for rapid response to emerging pathogens, making them vital in pandemic preparedness and outbreak containment strategies.

The post-COVID era has ushered in an acceleration of interest in recombinant DNA technologies, particularly in mRNA-compatible constructs and virus-like particles (VLPs) that mimic native viruses without carrying genetic material. Global public health initiatives are prioritizing the development of thermostable, needle-free, and adjuvant-enhanced recombinant formulations to boost vaccine access and coverage in low-resource settings. In parallel, recombinant vaccines are becoming central to personalized immunization strategies, especially in oncology and allergen desensitization, where antigen specificity and immune modulation are paramount. As R&D pipelines expand, recombinant vaccine development is expected to increasingly dominate the prophylactic and therapeutic vaccine landscape.

Which Disease Segments and Target Populations Are Driving Adoption?

The strongest momentum for recombinant vaccines is being observed in hepatitis, human papillomavirus (HPV), respiratory syncytial virus (RSV), and influenza segments. Widespread adoption of recombinant hepatitis B vaccines in national immunization programs, especially in Southeast Asia and Sub-Saharan Africa, has significantly reduced chronic infections and associated liver cancers. The inclusion of HPV vaccines in school-based programs is propelling recombinant vaccine usage among adolescents and young adults. Additionally, RSV vaccine rollouts for older adults and pregnant women-especially with the introduction of recombinant formulations-highlight the growing importance of life-course immunization approaches.

Pediatric populations, immunocompromised individuals, and geriatrics are emerging as high-priority targets for recombinant vaccine delivery. These groups benefit from recombinant formulations due to their superior safety profiles and reduced risk of adverse events. Furthermore, oncology vaccines leveraging recombinant tumor-associated antigens are under rapid clinical development, signaling a shift toward therapeutic applications. Public-private partnerships, GAVI support, and WHO prequalification are catalyzing recombinant vaccine inclusion in routine immunization schedules in developing countries. As global vaccination strategies evolve beyond childhood focus, recombinant vaccines are poised to address broader public health goals, including antimicrobial resistance reduction and cancer prevention.

What Are the Key Supply Chain and Regulatory Enablers?

Manufacturing scalability and process control are essential to the success of recombinant vaccine commercialization. Unlike traditional egg-based methods, recombinant platforms offer more predictable yields, reduced production timelines, and enhanced biosafety. Leading manufacturers are investing in single-use bioreactor systems, automated purification processes, and cold chain innovations to support global distribution. Additionally, the modular nature of recombinant vaccine production allows for multi-pathogen platforms that can be swiftly adapted to new disease targets, supporting resilience in future health crises.

From a regulatory standpoint, recombinant vaccines are benefitting from accelerated pathways in the U.S. FDA, EMA, and global regulatory bodies that prioritize high-need immunization products. The inclusion of recombinant vaccines in WHO’s emergency use listings, alongside expedited national licensing, is paving the way for rapid deployment during outbreaks. Moreover, pharmacovigilance frameworks and real-world evidence from post-marketing surveillance are continuously reinforcing the safety and efficacy profiles of recombinant products. Partnerships with contract development and manufacturing organizations (CDMOs) are further helping biotech innovators bridge capability gaps and scale recombinant vaccine production to meet growing global demand.

What Is Fueling the Sustained Growth of This Market?

The growth in the recombinant vaccines market is driven by several factors, most notably the increasing global focus on precision immunization, the expansion of life-course vaccination strategies, and the rising incidence of vaccine-preventable diseases. As healthcare systems seek to improve the efficacy, safety, and accessibility of immunization programs, recombinant technologies offer a scientifically validated and commercially scalable solution. The shift toward universal vaccination across all age groups, combined with governmental and donor agency support, is accelerating demand in both routine and outbreak response settings.

Technological innovation is also a major growth catalyst. Advancements in recombinant protein expression, nanoparticle delivery systems, and thermostabilization techniques are extending the reach of vaccines to rural and underserved areas. Continued investment in next-generation adjuvants and mucosal delivery methods is further enhancing the immunogenicity and patient acceptability of recombinant vaccines. Furthermore, the success of COVID-19 mRNA vaccines has increased global trust in recombinant platforms and validated their potential in combating emerging infectious diseases and cancer.

As pharmaceutical companies prioritize sustainable vaccine production and equitable access, recombinant vaccine technologies are becoming the backbone of future-ready immunization ecosystems. Market expansion is expected to intensify with new indications, broader regulatory support, and rising healthcare investments across middle-income nations.

SCOPE OF STUDY:

The report analyzes the Recombinant Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Vaccine Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines); Disease (Pneumococcal Disease, Cancer Disease, Hepatitis B Disease, Influenza Disease, DPT Disease, Other Diseases); Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers Distribution Channel)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

• AbbVie Inc.
• AstraZeneca plc
• Bavarian Nordic
• Bharat Biotech
• Clover Biopharmaceuticals
• CSL Limited
• Dynavax Technologies Corporation
• Emergent BioSolutions
• GlaxoSmithKline plc (GSK)
• Green Cross Corporation (GC Biopharma)
• Johnson & Johnson
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Panacea Biotec
• Pfizer Inc.
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• Vaxart, Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher. Show more